Table 1.
Patient characteristics at baseline
| Patient characteristic | Sunitinib (N = 12) |
|---|---|
| Age, years | |
| Median | 54 |
| Range | 34–79 |
| Sex, n (%) | |
| Male | 8 (67) |
| Female | 4 (33) |
| ECOG performance status, n (%) | |
| 0 | 11 (92) |
| 1 | 1 (8) |
| Time since diagnosis, years | |
| Median | 3 |
| Range | 0.2–9.0 |
| Tumor functionality, n (%) | |
| Nonfunctioning | 10 (83) |
| Functioning | 2 (17) |
| Gastrinoma | 2 (17) |
| Number of involved disease sites per patient, n (%) | |
| 1 site | 4 (33) |
| 2 sites | 5 (42) |
| 3 sites | 2 (17) |
| 4 sites | 1 (8) |
| Presence of distant metastases, n (%) | |
| Any, including hepatic | 12 (100) |
| Extrahepatic | 3 (25) |
| Involved disease sites, n (%) | |
| Liver | 12 (100) |
| Lymph node | 4 (33) |
| Pancreas | 4 (33) |
| Lung | 2 (17) |
| Bone | 1 (8) |
| Peritoneum | 1 (8) |
| Prior surgery, n (%) | |
| Yes | 9 (75) |
| No | 3 (25) |
| Prior radiation therapy, n (%) | |
| Yes | 1 (8) |
| No | 11 (92) |
| Number of prior systemic chemotherapy regimens, n (%) | |
| 0 | 6 (50) |
| 1 | 4 (33) |
| 2 | 0 |
| ≥3 | 2 (17) |
ECOG Eastern cooperative oncology group